PTPN11 and Miyoshi myopathy: These data supported that SHP2 inhibitors might be promising candidates for MM patients resistant to bortezomib chemotherapy and the combination of SHP2 inhibitors and BTZ might be a good choice to overcome the resistance of BTZ.